Genetic association studies have detected two trans-acting quantitative trait loci (QTL) on chromosomes 2, 6 and one cis-acting QTL on chromosome 11 that were associated with fetal hemoglobin (HbF) levels.
Introduction
Genome-wide and other genetic association studies have detected many single nucleotide polymorphisms (SNPs) in chromosomes 2, 6, and 11 that were associated with fetal hemoglobin (HbF) levels in normal individuals and in patients with sickle cell anemia and b thalassemia (Thein et al. 1987; Craig et al. 1996; Garner et al. 1998; Uda et al. 2008; Mtatiro et al. 2014) . These studies used either HbF protein levels-expressed as a percentage of total hemoglobin-or the percentage of all erythrocytes that had HbF detected by immunofluorescence (F-cells) as a quantitative trait. HbF is a tetramer composed of two a and two g-polypeptide subunits. The g-globin subunits, which characterize HbF, are encoded by two closely linked genes-from 5' to 3', HBG2 and HBG1 (together, HBG). The respective polypeptides of the g-globin genes differ by only a single amino acid in position 136; glycine in the G g chain (HBG2) and alanine in the A g chain (HBG1) (Schroeder et al. 1968 ). In adults, these genes are expressed at a ratio of 2:3 (Terasawa et al. 1980) . Expression quantitative trait loci (eQTLs) are genomic loci that lead to variability in mRNAs expression levels and can be identified by analyzing global RNA expression using the expression levels of genes as quantitative phenotypes. Differential expression of HBG in whole blood can be detected by mRNA analysis that may provide an understanding of whether eQTL associated with HBG affects the expression of one or both genes.
RNA sequence data (RNA-seq) and whole genome sequences from primary erythroid progenitors expressing HBG would provide the ideal data set to study cis and trans-acting elements that regulate HbF expression. However, such data are rarely available publicly. The Genotype-Tissue Expression (GTEx)-project provides an alternative resource to study HBG gene expression, the regulatory elements of these genes and the effects of genetic variation of these elements (GTEx_Consortium 2013). GTEx was launched in 2010 to create a publicly available database of genotype and tissue expression. Samples come from either deceased or surgical donor's organ/tissues. These human tissue samples then undergo RNAseq and genome-wide SNP analysis. The tissues sampled include peripheral blood, which contains reticulocytes that express hemoglobin genes. Reticulocytes account for about 10% of total hemoglobin synthesis.
We performed a genome-wide association study (GWAS) to detect eQTLs associated with expression of HBG in whole blood, other genes of the b-globin (HBB) gene cluster and with known HbF cis-and transacting regulators. In addition, we examined genes co-expressed with HBG1 to discover enriched pathways, studied upstream regulators of HbF co-expressed genes and performed correlation analysis between HBG and known HbF regulators. A similar correlation analysis included BCL2L1, a potential HbF activator we found in our analysis. We hypothesized that trans-acting elements that are transcription factors affect the expression of both HBG2 and HBG1, while the known cis-acting QTL in the promoter of HBG2 is likely to be associated with the expression of this gene only.
Results

Preliminary studies
GTEx whole blood RNA-seq data detected HbF eQTLs in BCL11A, HMIP and in the HBB gene cluster using HbF gene expression as a surrogate for HbF protein levels, validating the utility of this data set for examining HbF-associated eQTL ( (6:135418632_TTAC/T) on HBG1 and HBG2 expression in GTEx data set version 6. P-values are above genome-wide significance for rs1427407 (BCL11A, chr2) and rs9399137 (MYB, chr6) association with expression of both HBG genes. Rs10128556 (chr 11) is significantly associated with only HBG2 (pvalue of 2.60E-16) while it has no effect on HBG1(p-value 0.89) Het denotes heterozygous, and Homo, homozygous.
Genome-wide eQTL association analysis
Twenty-seven SNPs were eQTL associated with HBG1 (p-value ≤ 5 × 10−8). Of these 27, 21 were intergenic variants in the HMIP region on chromosome 6p, five were BCL11A variants on chromosome 2p, and one was on chromosome 11p ( Fig. 2A , Table S1 ). The SNP rs66650371, the functional 3-bp deletion in the MYB enhancer, is one of the most significant SNPs in the HMIP region. The most significant SNP of the five BCL11A variants was rs1427407, which in other studies was the functional SNP in the erythroid-specific enhancer of this gene (Bauer et al. 2013 ).
Forty-nine SNPs meeting genome-wide significance levels were eQTL for HBG2. Seventeen were intergenic variants in the HMIP region on chromosome 6, five were BCL11A variants on chromosome 2p, 26 were on chromosome 11p (Fig 2B, Table S2 ) and one was on chromosome 1. The most significant SNP in chromosome 11 was rs7482144 and this was associated only with the expression of HBG2; rs16912979, which is located in hypersensitive site (HS) 4 of the locus control region (LCR) of the HBB gene complex, was also associated solely with HBG2 expression. The SNP rs66650371 (MYB) and rs1427407 (BCL11A) were significantly associated with both HBG2 and HBG1. The conditional analysis of HBG1 showed that after adjusting for the effects of rs1427407, rs66650371, and rs7482144, there was no association on chromosome 2 or chromosome 6 (Fig. 2C , Table S3 ). Conditional analysis of HBG2 showed that no SNP was significantly associated with HBG2 expression after adjusting for rs7482144, rs1427407, and rs66650371 ( Fig. S1 , Table S4 ). There was no SNP with genome-wide significance associated with expression of BCL11A and ZBTB7A (Figs. S2, S3; Tables S5,   S6 ). One SNP on chromosome 6 was associated with MYB expression, another on chromosome 6 was associated with HBD expression, and one on chromosome 12 was associated with KLF1 expression (Figs.
S4, S5, S6; Tables S7, S8, S9).
Variants on chromosome 1, 2, 6, 7, 14, and 20 were significantly associated with HBB expression (Fig. S7 , Table S10 ).
Association of the erythroid-specific BCL11A enhancer variant rs1427407 with whole blood gene expression
Linear regression analysis showed that the genotype of rs1427407 was significantly associated with HBG1 and HBG2 expression in whole blood ( Table 2 . Effect of rs1427407 on whole blood gene expression. ENS_ID is ensemble gene ID, LogFC is log fold change, aveExpr is average expression, and adj.P.Val is FDR adjusted p-value.
HBG1 differential co-expression analysis
Twelve genes were differentially co-expressed with HBG1 after FDR p-value adjustment ( Table S11) .
The pathway enrichment analysis for the top100 co-expressed genes did not include any known pathway involved in HbF regulation among the top 10 enriched pathways. Of 452 upstream regulators that regulate the top100 HBG1 co-expressed genes, 360 regulated BCL2L1 (Table S12) . GATA1and KLF1 were also in top five statistically significant upstream regulators.
Correlation analysis between known and potential HbF regulators and HBG
The correlation between HBG1 and HBG2 normalized gene expression and the expression of BCL11A, KLF1, MYB, ZBTB7A, SIRT1 and BCL2L1 in the GTEx whole blood data set, showed that BCL2L1 had correlation coefficients of 0.59 and 0.55 for HBG1 and HBG2, respectively with a p value of 2.2E-16.
( Table 3) . Table 3 . Pearson correlation between HBG and known or potential HbF regulators using RNA-seq from 338 whole blood samples from GTEx.
Regulators
HBG1
In primary human fetal liver proerythroblasts, BCL2L1, KLF1, and SIRT1 were positively correlated with HBG expression with correlation coefficients of 0.93, 0.92, and 0.62, respectively; BCL11A and MYB were negatively correlated with HBG1 with correlation coefficients of -0.63, and -0.64, respectively;
ZBTB7A was weakly correlated with HBG1, and the p-value for association was not significant (Table 4) . 
Regulators
HBG1
Discussion
Among eQTL significantly associated with HBG expression 21 were intergenic variants in HMIP on chromosome 6p. The functional 3-bp deletion (rs66650371) was one of the most significant eQTL in this MYB enhancer (Farrell et al. 2011; Stadhouders et al. 2014 ). The SNP rs66650371 was in strong LD with 20 other SNPs in chromosome 6p in Europeans, South and East Asians, and admixed Americans (Table   S13) . A long non-coding or lncRNA containing the site of rs66650371was transcribed from this enhancer.
Its downregulation in an erythroid cell line that expressed adult hemoglobin (HbA) was associated with a 200-fold increase in HBG expression and a 20-fold increase in HbF (Morrison et al. 2017) . The eQTL at rs66650371 further supports the functional importance of this SNP. Five BCL11A SNPs in chromosome 2p were in very strong LD across populations ( Table S14) . The most significant, rs1427407, is a functional erythroid-specific enhancer variant that altered the expression of BCL11A (Bauer et al. 2013 ).
Both rs1427407 and rs66650371are trans-acting elements and had the same magnitude of effect on HBG1
and HBG2 (Fig. 1C, 1D; Fig. 3 ). These observations are consistent with our hypothesis that trans-acting elements affect expression of both g-globin genes. and HBG2, respectively.
The SNP rs10128556 in the pseudogene HBBP1 on chromosome 11p was in strong LD with rs7482144 and was reported to have an effect independent of rs7482144 in African American sickle cell disease patients and be the likely functional variant modulating cis-acting HbF gene expression (Galarneau et al. 2010 ). However, rs7482144 is located within the HBG2 promoter and highly linked to rs368698783 in HBG1 promoter. The SNP rs368698783 together with rs7482144 are associated with reduced methylation in six CpG sites flanking the transcription start site of HBG (Nagel et al. 1985; Ballas et al. 1991; Rahimi et al. 2015) . Many mutations have been described in the promoters of HBG2 and HBG1 that cause the phenotype of HPFH. For each of these mutations, depending on the affected gene, either HBG2 or HBG1usually comprises more than 90% of total g globin (Wood 2001 ). The T-C mutations at -175 and -173 in the promoter of HBG1 reactivated A g-globin gene expression in adult erythrocytes of transgenic mice while altering the binding of GATA-1 and Oct-1 and (Liu et al. 2005) . Moreover, a C-T polymorphism that is identical to rs7482144 but at position -158 relative to HBG1 affected HBG1 expression (Patrinos et al. 1998 ).
These results suggest that rs7482144 rather than rs10128556 is either the functional cis-acting element regulating HBG2 expression or the best surrogate for this element. In addition, rs16912979 in HS-4 of the LCR is also solely associated with HBG2 further supporting the effect of cis-acting elements on a single g-globin gene (Fig. 4, 5) . This SNP is a member of the 3-SNP T/A/T haplotype (rs16912979, rs7482144, rs10128556) that is exclusive to the AI haplotype and is associated with their high HbF (Vathipadiekal et al. 2016 ). The T allele of rs16912979 tags a predicted binding site for runt-related transcription factor 1 (RUNX1) in the palindromic region of 5′ HS-4. RUNX1 plays an important role in hematopoiesis and electromobility shift assays (EMSA) suggested an allele-specific binding of RUNX1 to 5′ HS-4 (Dehghani et al. 2016) . No common variants affected the expression of BCL11A. The BCL11A hypersensitive site variant rs1427407 is erythroid specific and in whole blood samples would impact BCL11A expression only in reticulocytes. However, BCL11A is expressed in leukocytes that are abundant in the blood. BCL11A expression in these nucleated cells with their greater transcriptional activity than reticulocytes would render an erythroid-specific signal impossible to detect. Our inability to find genes known to influence HBG1 in the co-expression analysis and a lack of correlation of known HbF regulators with HBG in GTEx data despite a strong relationship in fetal liver proerythroblasts might have a similar explanation and illustrate the main limitation of using GTEx data where globin synthesizing reticulocytes were likely to be <1% of all red blood cells (Means RT 2009) . Although few in number, reticulocytes are the only cells in the blood expressing globin genes, and RNA-seq provides sufficient data for most statistical analysis.
The unexpected correlation between BCL2L1 and HBG expression (r 0.58 & 0.55; p=2.30E-16) was validated in fetal proerythroblasts (r> 0.9). BCL2L1 is a member of bcl-2 gene family involved in antiapoptotic activities with an important role in erythropoiesis. Induction of bcl-x L (BCL2L1) expression by erythropoietin and GATA1 was critical for the survival of late proerythroblasts and early normoblasts (Gregory et al. 1999) .The upstream regulation analysis shows that BCL2L1 was regulated by 80 percent of the regulators that regulate the top 100 co-expressed genes. GATA1 and KLF13 are among these upstream regulators. These data and the correlation of BCL2L1 with HBG suggest a role for BCL2L1 in HbF regulation. Experimental validation to confirm the relationship between BCL2L1 and HBG and to pinpoint the mechanism through which BCL2L1 regulates HBG expression could lead to the discovery of potential new drug targets or molecules that can be used to induce HbF in sickle cell anemia and b thalassemia.
Cis-and trans-acting regulators have a differential effect on HBG1 and HBG2 expression. The transacting eQTLs of BCL11A and MYB enhancers affect expression of both g-globin genes. In contrast, only a single g-globin gene is affected by the cis-acting eQTL. HbF is the major modulator of the severity of both sickle cell anemia and b thalassemia and considerable effort is being made to develop methods to increase HBG expression for therapeutic purposes (Deng et al. 2014; Lettre and Bauer 2016) . Although clinical observations suggest that an increase of HBG2 alone has some benefit (Ballas et al. 1991; Teixeira et al. 2003; Alsultan et al. 2014) , modification of trans-acting elements that affect both HbF genes might have a greater effect on HbF levels and help force a more pancellular distribution that could be therapeutically important (Sankaran et al. 2011; Steinberg et al. 2014; Guda et al. 2015; Masuda et al. 2016 ).
Methods
Genome-wide eQTL association analysis
Whole blood normalized RNA-seq data, 1000 Genome imputed genotypes, and the covariates file of 338 donors were downloaded from the GTEx portal version 6. The covariates used in the original GTEx data analysis included 3 genome-wide genotype principal components (PCs), 35 Probabilistic Estimation of Expression Residuals (PEER) factors to be used as confounders, genotyping platform (Illumina HiSeq 2000 or HiSeq X), and sex (Consortium 2017) . We performed genome-wide eQTL analysis using
Efficient and Parallelizable Association Container Toolbox (EPACTS) (EPACTS 2017) and selected
SNPs with minor allele frequency (MAF) ≥ 0.01 and imputation quality score (R^2) ≥ 0.4 to reduce the rate of false association. We used the first 3 PCs to adjust for population substructure. We also used sex and platform as covariates to remove any bias introduced by these two components. The 35 PEER factors were used to adjust for batch effects and experimental confounders. This standard set of covariates were used in the models to detect eQTLs for HBG1, HBG2, BCL11A, KLF1, MYB, HBB, and HBD. To detect any significant association after adjusting for the most significant SNPs on chromosomes 2, 6, and 11, we tested association of normalized expression of HBG1 and HBG2 conditioned on the genotypes of rs7482144, rs1427407, and rs66650371. Only SNPs that reached genome-wide significance (p-value ≤ 5 × 10 -8 ) were considered statistically significant.
Preliminary studies
To reproduce the genetic association of known QTL variants with HBG expression using GTEx RNA-seq data from reticulocytes, three SNPs were selected based on their prior association with HbF levels in GWAS. We chose rs1427407 in the BCL11A erythroid-specific enhancer on chromosome 2p (Bauer et al. 2013) , rs10128556, which is in high linkage disequilibrium (LD) with the Xmn1 restriction polymorphism (rs7482144) on chromosome 11p (Galarneau et al. 2010) , and rs9399137 that is in perfect LD with the 3-base pair deletion (rs66650371) in the HBS1L-MYB intergenic polymorphism (HMIP) region on chromosome 6q (Farrell et al. 2011) . SNPs in LD with rs66650371and rs7482144 were chosen because GTEx pre-calculated eQTL did not contain these SNPs. The GTEx eQTL calculation tool was used to validate these associations in 338 whole blood samples available in the GTEx portal. We sought to validate the effect of a BCL11A erythroid-specific-enhancer SNP on HBG2 and HBG1 to confirm that genotype can be used to predict phenotype and vice versa.
Association of the erythroid-specific BCL11A enhancer variant rs1427407 with whole blood gene expression
We extracted the genotype of rs1427407 form GTEx data set version 6 and used these data to predict the impact of this SNP on global gene expression. The same covariates were used in the eQTL analysis, and
Linear Models for Microarray and RNA-seq Data (limma) were used to perform linear regression (Ritchie et al. 2015) . We used false discovery rate (FDR) to correct for multiple hypothesis testing.
HBG1 differential co-expression analysis
Since HBG2 expression is significantly associated with the genotype of rs7482144, we used HBG1 expression as a marker of expression of both g-globin genes. A gene expression matrix of normalized log expression of RNA-seq along with covariates including 35 PEER factors and sex from 338 whole blood samples were used as input for limma to perform differential analysis. We used FDR to correct for multiple testing. Using Ingenuity Pathways Analysis (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) we performed pathway analysis using the top100 co-expressed genes to see whether there was any enrichment in pathways involved in HbF regulation. In addition, we examined upstream regulators of the genes in the top100 HBG1 co-expressed gene list to identify HbF transcriptional regulators that can explain the observed gene expression changes.
Correlation analysis between known and potential HbF regulators and HBG expression
We performed Pearson correlation between HBG expression and the expression of BCL11A, KLF1, MYB, ZBTB7A, SIRT1 and BCL2L1 on 338 GTEx whole blood samples. These genes were selected because of their role or putative role as modulators of HBG expression, except for BCL2L1 which was selected based on our HBG1 co-expression and upstream regulators analysis (Jiang et al. 2006; Zhou et al. 2010; Masuda et al. 2016; Dai et al. 2017 ).
To replicate parts of our GTEx-based analysis, the same correlation analysis was done on data from erythroid samples acquired from Gene Expression Omnibus (GEO; accession number GSE59089) (Xu et al. 2015) . These data contained RNA-seq derived from primary human fetal liver proerythroblasts studied at different developmental stages after shRNA-mediated knockdown of Polycomb Repressive Complex 2 (PRC2) core subunits.
Data Access
Whole blood normalized RNA-seq data, 1000 Genome imputed genotypes, and the covariates file of 338 donors were downloaded from the GTEx portal version 6.
RNA-seq data from 15 erythroid samples were acquired from Gene Expression Omnibus (GEO; accession number GSE59089).
